Abstract
Clonal heterogeneity and clonal evolution have emerged as critical concepts in the field of oncology over the past four decades, largely thanks to the implementation of novel technologies such as comparative genomic hybridization, whole genome/exome sequencing and epigenetic analysis. Along with the identification of cancer stem cells in the majority of neoplasia, the recognition of intertumor and intratumor variability has provided a novel perspective to understand the mechanisms behind tumor evolution and its implication in terms of treatment failure and cancer relapse or recurrence. First hypothesized over two decades ago, clonal heterogeneity and clonal evolution have been confirmed in multiple myeloma (MM), an incurable cancer of plasma cells, almost universally preceded by a pre-malignant conditioned named monoclonal gammopathy of undetermined significance (MGUS). The genetic events and molecular mechanisms underlying such evolution have been difficult to dissect. Moreover, while a role for the bone marrow microenvironment in supporting MM cell survival, proliferation and drug-resistance has been well established, whether it is directly involved in driving evolution from MGUS to MM is at present unclear. We present in this review a historical excursus on the concepts of clonal heterogeneity and clonal evolution in MM with a special emphasis on their role in the progression from MGUS to MM; the contribution of the microenvironment; and the clinical implications in terms of resistance to treatment and disease relapse/recurrence.
Keywords: Clonal evolution, clonal heterogeneity, MGUS, microenvironment, multiple myeloma, plasma cell dyscrasia.
Current Cancer Therapy Reviews
Title: Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma
Volume: 10 Issue: 2
Author(s): Giada Bianchi and Irene M. Ghobrial
Affiliation:
Keywords: Clonal evolution, clonal heterogeneity, MGUS, microenvironment, multiple myeloma, plasma cell dyscrasia.
Abstract: Clonal heterogeneity and clonal evolution have emerged as critical concepts in the field of oncology over the past four decades, largely thanks to the implementation of novel technologies such as comparative genomic hybridization, whole genome/exome sequencing and epigenetic analysis. Along with the identification of cancer stem cells in the majority of neoplasia, the recognition of intertumor and intratumor variability has provided a novel perspective to understand the mechanisms behind tumor evolution and its implication in terms of treatment failure and cancer relapse or recurrence. First hypothesized over two decades ago, clonal heterogeneity and clonal evolution have been confirmed in multiple myeloma (MM), an incurable cancer of plasma cells, almost universally preceded by a pre-malignant conditioned named monoclonal gammopathy of undetermined significance (MGUS). The genetic events and molecular mechanisms underlying such evolution have been difficult to dissect. Moreover, while a role for the bone marrow microenvironment in supporting MM cell survival, proliferation and drug-resistance has been well established, whether it is directly involved in driving evolution from MGUS to MM is at present unclear. We present in this review a historical excursus on the concepts of clonal heterogeneity and clonal evolution in MM with a special emphasis on their role in the progression from MGUS to MM; the contribution of the microenvironment; and the clinical implications in terms of resistance to treatment and disease relapse/recurrence.
Export Options
About this article
Cite this article as:
Bianchi Giada and Ghobrial M. Irene, Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma, Current Cancer Therapy Reviews 2014; 10 (2) . https://dx.doi.org/10.2174/157339471002141124121404
DOI https://dx.doi.org/10.2174/157339471002141124121404 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pro-Inflammatory Cytokines and their Actions on the Metabolic Disturbances Associated with Cancer: Implications in Cachexia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry AIDS Vaccines and Reproductive Immunology
Current Immunology Reviews (Discontinued) Fangchinoline, an Extract of the <i>Stephania tetrandra</i> S. Moore Root, Promoted Oxidative Stress-induced DNA Damage and Apoptosis and Inhibited Akt Signaling in Jurkat T Cells
Current Molecular Pharmacology Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular Dystrophy
Current Gene Therapy Patent Selections
Recent Patents on Biomarkers Role of Flavonoids in Future Anticancer Therapy by Eliminating the Cancer Stem Cells
Current Stem Cell Research & Therapy Versatile Applications of microRNA in Anti-Cancer Drug Discovery: From Therapeutics to Biomarkers
Current Drug Discovery Technologies Mechanisms of Stem Cells and Their Secreted Exosomes in the Treatment of Autoimmune Diseases
Current Stem Cell Research & Therapy The Promise of Slow Down Ageing May Come from Curcumin
Current Pharmaceutical Design Beneficial Outcomes of Cancer Therapeutic Modalities Based on Targeting Apoptosis
Current Drug Targets A New Approach to Tubacin
Letters in Organic Chemistry High Throughput Cell-Based Screening of Biodegradable Polyanhydride Libraries
Combinatorial Chemistry & High Throughput Screening Osteoprotegerin Positively Regulates Hematopoietic Progenitor Cells
Current Stem Cell Research & Therapy Thiarabine, 1-(4-Thio-β-D-arabinofuranosyl)cytosine. A Deoxycytidine Analog With Excellent Anticancer Activity
Current Medicinal Chemistry The Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway as a Therapeutic Target for the Treatment of Human Acute Myeloid Leukemia (AML)
Current Signal Transduction Therapy New Strategies in the Chemotherapy of Leukemia: Eradicating Cancer Stem Cells in Chronic Myeloid Leukemia
Current Cancer Drug Targets Targeting STAT3 Enzyme for Cancer Treatment
Mini-Reviews in Medicinal Chemistry Reprogramming of Molecular Switching Events in UPR Driven ER Stress: Scope for Development of Anticancer Therapeutics
Current Molecular Medicine Potential of Plant-Derived Natural Products in the Treatment of Leukemia and Lymphoma
Current Drug Targets Baicalein - An Intriguing Therapeutic Phytochemical in Pancreatic Cancer
Current Drug Targets